ClinicalTrials.gg

Program

PfSPZ-LARC2 Vaccine

Its studies are mostly in Malaria, Falciparum, led by Sanaria.

Furthest: phase 2, since Jun 17, 20264 company-led studies, 3 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanaria43 open or runningphase 2since Jun 17, 2026Oct 18, 2024Aug 30, 2027phase 1 · NCT06862453

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2024First study: phase 1 study in Malaria, FalciparumFirst studyNCT06652737 · 75 enrolled · Burkina Faso
  2. Mar 2, 2025Phase 1 study in Malaria, FalciparumNCT06862453 · 42 planned · Germany
  3. Jun 17, 2026Phase 2 study in Malaria, FalciparumPhase 2 reachedNCT07675785 · 300 planned · Mali
  4. Jul 16, 2026Phase 1 study in Malaria, FalciparumNCT07730177 · 45 planned · Burkina Faso

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Malaria, FalciparumNCT06862453
  2. Dec 2027Primary completion: phase 1 study in Malaria, FalciparumNCT07730177
  3. Jul 15, 2028Primary completion: phase 2 study in Malaria, FalciparumNCT07675785

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“PfSPZ-LARC2 Vaccine”name, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07730177Malaria, Falciparum · Burkina Faso1Not yet recruitingDec 202745
NCT07675785Malaria, Falciparum · Mali2RecruitingJul 15, 2028300
NCT06862453Malaria, Falciparum · Germany1RecruitingAug 30, 202742
NCT06652737Malaria, Falciparum · Burkina Faso1CompletedFeb 18, 202675

How it is read

Names in the registry

  • “PfSPZ-LARC2 Vaccine”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.